Summary：**Scientists Discover Biological Aging Clocks That Predict Health and Disease Risks** *This review

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

**Scientists Discover Biological Aging Clocks That Predict Health and Disease Risks**
*This review outlines the state of the art of biological clocks and how they could help understand pathobiology, reduce the burden of disease and extend healthspan.*

### Introduction
Researchers worldwide are turning the most often associated with DNA methylation patterns. Recent studies show that these molecular timers can forecast not only chronological age but also susceptibility to cardiovascular disease, neurodegeneration, and metabolic disorders. By translating epigenetic signals into actionable risk scores, the field is moving from descriptive biomarkers toward predictive tools that could reshape preventive medicine.

### Key Developments
In the past 18 months, three breakthroughs have accelerated the clock’s clinical relevance. First, a multi‑tissue epigenetic clock developed by the Horvath lab now integrates blood, saliva, and buccal swab data, improving accuracy across diverse populations. Second, machine‑learning models trained on longitudinal cohorts have identified specific CpG sites linked to inflammation and insulin resistance, offering mechanistic insight beyond mere age estimation. Third, wearable‑compatible assays that measure methylation changes from fingertip‑prick samples are entering pilot trials, promising real‑time monitoring of biological age in everyday settings.

### Industry Analysis
The surge in interest has attracted both established diagnostics firms and agile biotech startups. Companies such as Altos Labs and Calico Life Sciences are investing heavily in clock‑based platforms, while newer entrants like GlycanAge and MyDNAge are commercializing direct‑to‑consumer tests. Analysts project the global market for aging‑related biomarkers to exceed $4 billion by 2028, driven by employer wellness programs, insurance risk‑assessment tools, and geriatric care pathways. Regulatory bodies are beginning to draft guidance on validation standards, recognizing that clinical utility hinges on demonstra